transforming the treatment of

Low Back Pain

QUICK, PERCUTANEOUS PROCEDURE WITH SHORT RECOVERY - PATIENTS UP AND WALKING IN 2 HOURS

EFFECTIVE PAIN RELIEF AND REDUCTION OF DISABILITY

DISC AUGMENTATION AND MOTION PRESERVATION

CURRENT SOLUTION

Years of development to refine and optimize Hydrafil™​

The ReGelTec Hydrafil system injects an implant for nucleus pulposus augmentation as a viscous fluid which sets up in situ into one solid cohesive hydrogel within the disc annulus that effectively seals the access site and minimizes the risk of expulsion.​

  • Simple percutaneous procedure​

  • Biomechanical properties validated​

  • Mitigates risk of expulsion​

THE REGELTEC ROADMAP

Hydrafil™​ Development Roadmap

2004-2014

First generation hydrogel (Gelifex) developed and tested; Extensive R&D to refine  second generation for specific requirements

2014-2018

Continued development and testing of the hydrogel to address challenges with first generation

2018

ReGelTec incorporated to develop second generation hydrogel and raised Seed Round of financing

2018-2020

Pre-clinical studies initiated to confirm gel’s injectability and durability to 24+ months

2020

Initiated Early Feasibility Study in Colombia for proof of principle (20 patients) and also completed Series A financing and received FDA Breakthrough Device Designation

Get in Touch

​ReGelTec is a medical device company that is developing the next generation of minimally invasive spinal implants for lower back pain and degenerative disc disease.